Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
183 hedge funds and large institutions have $1.61B invested in Dicerna Pharmaceuticals, Inc. in 2021 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 55 increasing their positions, 67 reducing their positions, and 22 closing their positions.
55% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 22
15% more capital invested
Capital invested by funds: $1.4B → $1.61B (+$214M)
6% more funds holding
Funds holding: 173 → 183 (+10)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
18% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 67
38% less call options, than puts
Call options by funds: $5.27M | Put options by funds: $8.48M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MC
Maverick Capital
Dallas,
Texas
|
+$34.6M |
| 2 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$27.7M |
| 3 |
Morgan Stanley
New York
|
+$20.5M |
| 4 |
AG
Artal Group
Luxembourg
|
+$20.4M |
| 5 |
BM
Bridger Management
New York
|
+$15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$44.9M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$36.1M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$21M |
| 4 |
Renaissance Technologies
New York
|
-$13.8M |
| 5 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$11.6M |
DRNA Hedge Fund Activity: Q1 2021 in Review
183 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q1 2021, worth a combined $1.61B — up 15% from $1.4B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new DRNA positions and 22 closed out — a net gain of 12 holders — while 55 added to existing stakes and 67 trimmed.
The largest buyer was Maverick Capital, opening a new position worth an estimated $34.6M. The largest seller was Point72 Asset Management, cutting an estimated $44.9M.
- 183 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q1 2021, up from 173 in Q4 2020.
- Funds reported $1.61B of Dicerna Pharmaceuticals, Inc. stock for Q1 2021, up 15% quarter-over-quarter.
- 34 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q1 2021 and 22 closed out, a net change of +12 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q1 2021 was Maverick Capital, an estimated $34.6M added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q1 2021 was Point72 Asset Management, an estimated $44.9M sold.
Based on aggregated 13F filings for Q1 2021.